Suzanne Shelley, Contributing Editor

Persistent drug shortages are mostly attributable to manufacturing quality problems, but the economics of low-margin generic manufacturing challenge the industry

As rare diseases have emerged as a market opportunity for pharma over the past several years, industry practices are beginning to stabilize

The eye-popping price tag on the hepatitis C drug, from Gilead Sciences, has prompted unprecedented pushback from payers

A rising flow of new, expensive therapies is transforming relationships among payers and providers. Manufacturers will have to react nimbly to the changes

Despite proven medical value, coupon and copay offset programs continue to draw fire from insurers; meanwhile, will the programs extend to ACA insureds?

Essential for approving some new products, biomarkers are becoming integrated with patient therapies

Health systems and community oncologists are fighting over a preferred position as care providers, while payers tighten purse strings

While awaiting the effects of the Affordable Care Act on PAPs, industry and its service providers wrestle with conflicting priorities

More so than other classes of drugs, making choices about drugs for mental health conditions require everyone around the patient to be well informed